C12N 2310/311
Phosphotriesters
C12N2310/311 (Phosphotriesters) appears on 54 US grants and 72 published applications in this corpus.
Search patents in C12N- Granted patents
- 54
- Published applications
- 72
- Assignees
- 37
- Inventors
- 114
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 6 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 7 |
| 2004 | 2 | 9 |
| 2005 | 1 | 2 |
| 2006 | 0 | 0 |
| 2007 | 3 | 3 |
| 2008 | 2 | 0 |
| 2009 | 2 | 2 |
| 2010 | 3 | 3 |
| 2011 | 3 | 1 |
| 2012 | 1 | 2 |
| 2013 | 0 | 2 |
| 2014 | 0 | 2 |
| 2015 | 2 | 3 |
| 2016 | 1 | 2 |
| 2017 | 3 | 4 |
| 2018 | 2 | 1 |
| 2019 | 1 | 6 |
| 2020 | 0 | 4 |
| 2021 | 2 | 1 |
| 2022 | 3 | 6 |
| 2023 | 3 | 2 |
| 2024 | 1 | 2 |
| 2025 | 1 | 0 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases7 Apr 2026US 12,595,479 B2Children's Medical Center Corporation
- Nuclease-mediated genome editing of primary cells and related kits24 Mar 2026US 12,584,149 B2The Board of Trustees of the Leland Stanford Junior University
- Exosomal loading using hydrophobically modified oligonucleotides10 Mar 2026US 12,571,004 B2University of Massachusetts
- Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use8 Jul 2025US 12,351,598 B2Tallac Therapeutics, Inc.
- Polynucleotide constructs14 May 2024US 11,981,703 B2Sirius Therapeutics, Inc.
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- Antisense RNA (asRNA) Technology and Use Thereof24 Sep 2026US 2026/0286353 A11Globe Health Institute LLC
- Asymmetric Short Duplex RNA with Interspersed Deoxyribonucleotides as a Gene Silencing Technology and Use Thereof16 Jul 2026US 2026/0201377 A11Globe Health Institute LLC
- Exosomal loading using hydrophobically modified oligonucleotides9 Jul 2026US 2026/0193678 A1University of Massachusetts
- Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use23 Apr 2026US 2026/0109728 A1Tallac Therapeutics, Inc.
Most cited
By later US patents
- Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved663US 5,403,711 AUniversity of Iowa Research Foundation · 1995
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999
- Methods for blocking the expression of specifically targeted genes334US 5,491,133 AUniversity of Iowa Research Foundation · 1996
- Three component chimeric antisense oligonucleotides254US 5,849,902 AOligos Etc. Inc. · 1998